CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumours, announces that KJ-C2320, an allogeneic CAR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback